Analytical Data
-
Gene name
HLA-C*03:04&B2M&KRAS G12D(GADGVGKSAL) Tetramer
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
QAV56463.1 (G25-T305)&P61769
-
Expression Region
QAV56463.1 (G25-T305)&P61769 (I21-M119)&GADGVGKSAL
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-C*03:04/B2M/KRAS G12D tetramer is a crucial research tool designed to study immune responses against the KRAS G12D mutation, a common driver in several cancers, particularly pancreatic and colorectal cancers. The KRAS gene encodes a protein that is integral to cell signaling pathways controlling cell proliferation and survival. The G12D mutation results in a constitutively active form of the KRAS protein, contributing to tumorigenesis. Harnessing the HLA-C*03:04 molecule, which presents peptides derived from this mutated protein on the surface of antigen-presenting cells, researchers aim to identify and characterize T-cell responses specific to KRAS G12D. The B2M (Beta-2-microglobulin) component is essential for the stability and expression of the HLA molecule. Utilizing this tetramer, scientists can isolate and analyze T cells that respond to KRAS G12D, providing insights into the adaptive immune system's ability to recognize cancer cells bearing this mutation. This research is significant for developing effective cancer immunotherapies, as understanding T-cell recognition can inform the design of vaccines and adoptive T-cell therapies targeting KRAS mutations, ultimately improving patient outcomes in KRAS-driven cancers.
